Society for Translational Oncology navigateright Episode
Aiko Nagayama, MD, PhD
Massachusetts General Hospital
Triple negative breast cancer (TNBC), defined by the lack of hormone receptors and the absence of HER2 overexpression, represents 15% to 20% of all breast cancers and has heterogeneous biology with poor prognosis. There is no approved targeted therapy for TNBC, which calls for a better treatment option. Here we report progress in ongoing studies involving (a) potential biomarkers identified in the profile of serial biopsy TNBC samples from patients who were treated with IMMU-132 and (b) the synthetic lethal target screening by whole genome CRISPR/Cas9 knockout library in human TNBC cell line models.
These lectures are designed to meet the educational needs of physicians and scientists in academic and practice settings who wish to advance their knowledge of the research into new treatments and improve their competence in the care of patients with cancer.